Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Has Consensus Price Target of $3.83

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) have been assigned an average rating of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $3.83.

Several brokerages have recently issued reports on NAUT. Leerink Partners assumed coverage on Nautilus Biotechnology in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 price target on the stock. Zacks Research raised Nautilus Biotechnology to a “hold” rating in a research report on Wednesday, September 30th. Weiss Ratings downgraded Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Finally, Roth Capital initiated coverage on Nautilus Biotechnology in a report on Tuesday, September 29th. They issued a “buy” rating and a $3.50 target price on the stock.

Institutional Investors Weigh In On Nautilus Biotechnology

Hedge funds have recently modified their holdings of the business. CTC Alternative Strategies Ltd. acquired a new stake in shares of Nautilus Biotechnology in the first quarter worth $48,000. TD Waterhouse Canada Inc. increased its position in Nautilus Biotechnology by 1,500.0% during the second quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after acquiring an additional 15,000 shares during the period. Public Employees Retirement System of Ohio bought a new position in Nautilus Biotechnology during the first quarter worth $75,000. Callan Family Office LLC acquired a new position in Nautilus Biotechnology during the 2nd quarter valued at $49,000. Finally, Squarepoint Ops LLC acquired a new position in Nautilus Biotechnology during the 2nd quarter valued at $63,000. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Price Performance

Shares of NAUT opened at $2.44 on Tuesday. The company has a market capitalization of $310.49 million, a PE ratio of -5.42 and a beta of 0.73. Nautilus Biotechnology has a one year low of $0.84 and a one year high of $4.31. The company’s fifty day moving average price is $1.42 and its 200 day moving average price is $2.09.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million. Analysts anticipate that Nautilus Biotechnology will post -0.52 earnings per share for the current year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.